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Abstract
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The advent of major histocompatibility complex (MHC) tetramer technology has been a major
contribution to T cell immunology, because tetramer reagents permit detection of antigen-specific
T cells at the single-cell level in heterogeneous populations by flow cytometry. However, unlike
MHC class I tetramers, the utility of MHC class II tetramers has been less frequently reported.
MHC class II tetramers can be used successfully to enumerate the frequencies of antigen-specific
CD4 T cells in cells activated in vitro, but their use for ex vivo analyses continues to be a problem,
due in part to their activation dependency for binding with T cells. To circumvent this problem,
we recently reported the creation of a new generation of reagents called MHC class II dextramers,
which were found to be superior to their counterparts. In this review, we discuss the utility of class
II dextramers vis-a-vis tetramers, with respect to their specificity and sensitivity, including
potential applications and limitations.

Introduction

Author Manuscript

Historically, studies related to the detection and functionalities of antigen-specific T cells at
the single-cell level have been limited because the appropriate reagents and tools were not
available. Commonly employed readouts included T cell proliferation assays based on
incorporation of tritiated 3[H]-thymidine or 5-bromo-2'-deoxyuridine (BrdU);
Carboxyfluorescein succinimidyl ester (CFSE)-labelling; enzyme-linked immunospot
(ELISPOT) assays; limiting-dilution analysis (LDA); and intracellular cytokine analysis [1–
5]. Although most of these assays are helpful in ascertaining antigen-specific T cell
responses in mixed cell cultures at the population level, accurate enumeration of the
frequencies of antigen-specific T cells at the single-cell level has been a major limitation.
Even assays like ELISPOT or cytokine-analysis can be prone to errors because it is difficult
to eliminate the contribution of bystander T cells that can be non-antigen-specifically
activated, leading to the possibility of overestimating the antigen-specific T cells [1].
Similarly, although LDA permits analysis of antigen-specific T cells at the single cell-level,
this assay can never be routinely practical due to both the need to repeatedly activate the
cells and the laborious nature of the assay [1, 6].
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These circumstances changed, however, with the publication of a 1996 landmark paper by
Altman et al. describing the creation of major histocompatibility complex (MHC) class I
tetramer technology; the tetramer reagents were found to be valuable in enumerating the
frequencies of antigen-specific CD8 T cells by flow cytometry [7]. In 1998, Kappler’s group
provided a similar platform for CD4 T cells by generating peptide-tethered MHC class II
tetramers [8]. These discoveries enabled researchers to determine the specificity of antigenresponsive T cells, particularly with respect to their appearance, disappearance and/or
persistence in both basic and clinical research investigations (Table 1). MHC tetramers can
be defined as artificially created soluble fluorochrome-conjugated MHC molecules
assembled with peptides of interest. Their binding to antigen-specific T cells is captured by
flow cytometry using the signals emitted by fluorochromes as readouts. However, some
issues have continued to persist related to the inherent inability of MHC class II tetramers to
bind CD4 T cells, especially low-affinity T cell receptor (TCR)-bearing autoreactive T cells,
in spite of the fact that they are antigen-specific [9, 10]. To alleviate this problem, we
created a newer version of tetramers called MHC class II dextramers for various
autoantigens and successfully tested their utility in several experimental autoimmune and
infectious disease models [11–15]. In this review, we discuss the utility of MHC class II
dextramer reagents, most importantly their advantages over tetramers, as well as potential
applications and limitations (Table 2). Nonetheless, for extensive details on the derivation
and use of MHC class II tetramers, readers are encouraged to consult other excellent reviews
published by various groups [9, 10, 16, 17].

What are MHC class II tetramers and dextramers and how are they created?
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To understand the derivation of MHC class II tetramers and dextramers, it is useful to
understand how MHC molecules display peptides for recognition by T cells. In contrast to
MHC class I molecules that are composed of a single alpha chain supported by β2microglobulin as a scaffolding molecule, MHC class II molecules are made up of two
chains, α and β. While the peptide-binding groove in the MHC class I molecule is formed by
the participation of α1 and α2 domains, the α1 and β1 domains from their corresponding
chains within the MHC class II molecules take part in the formation of grooves to which the
peptides can anchor. The peptides thus displayed by MHC class I and MHC class II
molecules are recognized by CD8 or CD4 T cells, respectively, and CD8 and CD4
molecules act as co-receptors by binding to the corresponding MHC molecules [18].
Nonetheless, it should be noted that the affinity of T cell recognition of MHC-displayed
peptides is weak (KD~ 0.1–500 µM), and engagement of multiple TCRs with as many
multiple MHC-peptide complexes favors stability of their interactions, leading to enhanced
avidity [19, 20].
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The creation of tetrameric reagents requires expression of soluble MHC molecules that
represent the extracellular portions in each class of MHC molecule [7, 8]. The presence of a
single α chain may offer some advantage in allowing MHC class I molecules to be
expressed more easily than MHC class II molecules in which both α and β chains must stay
together so peptides can be displayed in the MHC clefts. Several strategies have been
successfully employed for the expression of MHC class II molecules for various alleles in
both mice and humans [8, 21–24]. Expression of soluble MHC class II molecules requires
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the creation of two constructs, one each for α and β chains. A BirA site for biotinylation is
introduced into one of the two chains, usually the α chain (Fig 1).
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To express soluble molecules, various mammalian and non-mammalian expression systems
have been used [9, 25–27]. However, it is to be noted that creation of MHC constructs
depends on the intended use of the soluble molecules. Three major approaches are
commonly used. (1) Derivation of peptide-tethered soluble MHC molecules. In this
approach, the nucleotide sequence for the desired peptide is covalently tethered to the Nterminus of the β chain such that the peptide-containing soluble MHC molecules are
expressed directly [8, 23]. Two advantages have been noted with this approach: (i) the
peptide-bound MHC molecules are readily available for downstream applications, so the
loss/instability of peptides is not an issue [8, 27]; and (ii) the covalently assembled peptides
may provide stability for MHC monomers during protein expression [8, 9]. The major
disadvantage is the need to generate constructs individually for each peptide of interest. (2)
Derivation of soluble, empty MHC molecules. Here, α and β chains without peptide
sequences are expressed to obtain empty molecules, and the desired peptides are then loaded
exogenously to generate peptide-bound MHC complexes. Technically, this approach is
versatile and desirable, but the stability of peptides within the groove can be an issue [28–
30]. (3) Derivation of soluble MHC molecules containing class II-associated invariant chain
peptide (CLIP). This approach is similar to approach 1 as described above, but instead of
tethering the specific peptide of interest to the N-terminus of the β chain, the CLIPconjugated sequence with a site for thrombin cleavage is inserted covalently to the Nterminus of the β chain. As a result, upon protein expression, the CLIP is cleaved by
thrombin to obtain empty MHC molecules, into which peptides of interest can be loaded
exogenously by a peptide-exchange reaction similar to that employed in approach 2 [21, 22,
31].
In all of these approaches, however, because it is possible for α and β chains to separate
during expression, it is a common practice to insert leucine-zipper dimerization motifs from
the transcription factors Fos (3.98 KDa) and Jun (3.92 KDa) to the α and β chains,
respectively, of MHC class II molecules [23, 32, 33]. By virtue of high-affinity binding
between Fos and Jun proteins (KD 5.4 × 10−8 M; [34]), the α and β chains are expected to
stay together as single monomers during protein expression, as well as in the downstream
steps of protein purification, multimerization and staining by flow cytometry. We commonly
employ approaches 1 and 3 in our routine tetramer and dextramer preparation.
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The purified soluble MHC class II monomers are first biotinylated using biotin ligase (BirA)
(Fig 1). While the peptide-tethered biotinylated proteins are directly multimerized using
streptavidin (SA) conjugated with fluorochromes, such as phycoerythrin (PE) or
allophycocyanin (APC), the CLIP-tethered proteins are first subjected to thrombin cleavage
to release the CLIP, and the empty molecules are then assembled with peptides in the
peptide-exchange reaction, followed by multimerization with SA-fluorochromes [21–23].
Although the latter approach is versatile in that we can generate reagents for multiple
antigens by loading the peptides exogenously into empty MHC molecules, we noted a few
limitations. First, peptides that are readily soluble in water or PBS can be reliably used to
prepare the reagents, and addition of dimethyl sulfoxide to enhance the solubility of peptides
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did not yield better results. Second, the sensitivity of tetramers and dextramers generated for
some peptides was lower than that could be achieved with the reagents generated from the
use of covalently tethered MHC molecules (unpublished observations).
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To prepare multimeric MHC-peptide complexes using SA-fluorochrome conjugates, it is
important to note that each SA can assemble up to four biotinylated MHC molecules. Hence,
tetramers typically are expected to possess up to four peptide-bound biotinylated MHC
molecules. In contrast to tetramers, the dextramers offer an advantage of assembling more
peptide-bound MHC molecules – up to 20 per dextran molecule [15, 35]. Structurally,
dextramers contain dextran backbones, which are polymers of glucose molecules attached
through 1–6 and 1–3 linkages [35]. Each dextran molecule carries multiple moieties of SA
to which biotinylated peptide-tethered MHC molecules can be assembled [35]. Therefore,
dextramers can yield MHC-peptide complexes of large molecular weight, allowing them to
engage multiple TCRs – more than could be achieved with tetramers.

Author Manuscript

To prepare the dextramers, we use dextran molecules (kind gift from Immudex, Denmark) at
a working concentration of 3.2 × 10−8 M. Conjugation of dextran molecules with MHCpeptide molecules depends on the number of SA-fluorochrome-assembled moieties available
in the dextran backbone. For example, a dextran-PE backbone containing 6.6 SA moieties
has a molar ratio of 19.8 (6.6 × a valency of 3). Therefore, each mole of dextran-PE can be
assembled with 19.8 moles of MHC class II monomers. We usually assemble 21 to 22 µg,
equivalent to 3.17×10−10 moles of MHC class II monomers (~68 KDa) with 1.6 × 10−11
moles of dextran-PE [15]. On a reaction basis, we routinely use PE-dextramers containing
6.3 × 10−12 moles, equivalent to 0.45 µg of MHC protein (~3.8 × 1012 molecules), to stain 1
× 106 cells [15]. Likewise, one mole of dextran-APC with a molar ratio of ~8.7 is used to
assemble 8.7 moles of MHC class II monomers. To prepare APC-dextramers, we use ~9.5 to
10 µg of MHC class II protein, equivalent to 1.39 × 10−10 moles, to assemble 1.6 × 10−11
moles of dextran-APC; and to stain 1 × 106 cells, 2.78 × 10−12 moles (0.2 µg; /~1.67 × 1012
MHC monomers) are used. Overall, the amount of MHC protein needed to prepare
dextramer-APC is half the amount needed to prepare dextramer-PE, but the staining
intensities obtained by the two reagents are comparable [15]. For routine use, the reaction
conditions for each dextramer reagent are to be optimized. We found that staining at room
temperature for a minimum of 30 minutes in growth medium (RPMI with 2.5% fetal bovine
serum and interleukin-2, pH 7.63) was optimum for various MHC class II alleles assembled
with a wide range of self- and foreign antigens [11, 14, 15].

Are MHC class II dextramers better reagents than MHC class II tetramers?
Author Manuscript

During the past 10 to 15 years, we have been using MHC class II tetramers in various
autoimmune disease models in mice, primarily experimental autoimmune encephalomyelitis
(EAE) induced with myelin proteolipid protein (PLP) 139–151 and myelin oligodendrocyte
glycoprotein (MOG) 35–55; amoebic encephalitis; experimental autoimmune myocarditis
(EAM) induced with cardiac myosin heavy chain (Myhc)-α 334–352; and experimental
autoimmune uveoretinitis induced with interphotoreceptor retinoid-binding protein 201–216
[11, 15, 23, 33, 36–42]. Although the tetramer reagents were helpful, their use was largely
limited to enumerating the frequencies of antigen-specific CD4 T cells in cultures activated
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in vitro, and the direct ex vivo analysis of antigen-sensitized cells was a persistent problem.
Enrichment procedures involving the use of antibodies to fluorochromes like PE to enrich
the tetramer-PE-bound CD4 T cells by magnetic separation followed by extrapolating their
frequencies to the total number of T cells have been commonly employed in the field [16,
22, 43, 44]. In these settings, the use of enzymes like protein tyrosine kinase inhibitors
(PKIs) (e.g., Dasatinib, Bristol-Myers Squibb) prior to tetramer staining and enrichment
procedures appears to enhance the sensitivity of tetramers [45, 46]. These methods can be
labor intensive, and time consuming. In addition, technically, there also exists a possibility
of non-antigen-specific cells to be present as contaminants in the enriched populations
necessitating the use of multiple surface markers to eliminate them [16]. Likewise,
peripheral blood mononuclear cells (PBMCs) from humans are usually stimulated with
antigen-pulsed autologous antigen-presenting cells (APCs) for up to ~7 days prior to
enrichment procedures [47]. Although these analyses may yield valuable information,
absolute enumeration of the frequencies of antigen-specific T cells can be prone for errors
leading to inaccurate estimations of their repertoire sizes. In some instances, frequencies of
antigen-specific T cells can be detected only marginally higher than the background staining
with the control tetramers because of difficulties in differentiating background staining from
the specific tetramer staining [48]. To overcome these limitations with tetramers, we made
efforts to create dextramers utilizing the dextran reagents conjugated with various
fluorochromes (kind gift from Immudex, Denmark) for IAs/PLP 139–151, IAb/MOG 35–55,
and IAk/Myhc-α 334–352 [15]. We found that dextramers, but not tetramers, were helpful in
enumerating the frequencies of antigen-specific CD4 T cells ex vivo in all the above models
[15]. In addition, we noted that the detection sensitivity of dextramers could be increased by
at least 4- to 5-fold compared with tetramers. Similarly, the specificity of staining obtained
with dextramers was better than that could be achieved with tetramers, as background
staining with the control dextramers was negligible [15]. One other group recently reported
similar observations by generating the dextramers for human MHC class II allele, HLA-DR1
[49]. We think that dextramers consisting of multiple MHC-peptide complexes may more
easily engage with multiple TCRs, leading to enhanced stability of dextramer-T cell
interactions. As such, the dextramer-bound T cells are less likely to be detached during
various steps in the staining reactions.

Author Manuscript

It is a common belief that tetramers bind poorly to low-affinity TCR-bearing T cells,
because their binding depends on the activation status of T cells, and tetramers therefore are
unlikely to bind the resting cells even if they are antigen-responsive [33, 50–52]. We and
others have previously reported that the tetramer+ cells were found almost exclusively
within the activated (CD4high/CD25+) population [33, 47, 50, 51]. We had proposed that the
activation status of cells may result in the reorientation or change in the configuration of the
TCR and cell surface molecules leading to increase in the avidity of TCR-MHC binding
[33]. To overcome this limitation, we had previously shown that antigen-responsive, rested
cells can be made to bind with tetramers by first exposing the cells to neuraminidase
(NASE), which essentially promotes T cell activation by an unknown mechanism [15, 23,
33]. In addition, removal of sialic acid residues from the surface of T cells by NASEtreatment may increase TCR affinity as shown with an insulin-insulin receptor system [53].
We verified that the dextramers can detect rested cells without the need for NASE-
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treatment, thus overcoming the activation dependency problem noted with tetramers. Based
on these successes, we expanded the utility of dextramers to detect antigen-specific CD4 T
cells in target organs, such as brains in EAE mice and hearts in EAM mice, by flow
cytometry [11, 15]. More importantly, we showed for the first time that MHC class II
dextramers can be used to detect antigen-specific CD4 T cells in situ directly, both in the
brain and heart in EAE and EAM models, respectively, by confocal microscopy without
having to amplify the fluorochrome signals using secondary antibodies, which had been the
case with MHC class I tetramers [12, 13, 54, 55]. This modality of in situ staining
considerably reduced the duration of the process to less than a day (~12 hours), as compared
to up to 3 days with MHC class I tetramers [54, 55]. Furthermore, the amount of reagent
needed per in situ reaction is 2.5 µg/ml, which is significantly less than required with
tetramers (20 µg/ml) [15, 56].
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By extending the utility of dextramers to phenotype antigen-specific CD4 T cells in relation
to cytokine-producing cells, we noted the unexpected finding that only a fraction of
dextramer+ CD4 T cells are capable of producing Th cytokines, while the majority of
cytokine-producing cells lie within the dextramer− CD4 T cell populations (unpublished
preliminary observations). Using IAs/PLP 139–151 and IAb/MOG 35–55 dextramers in the
EAE system and IAk/Myhc-α 334–352 dextramers in the EAM system, we are now
phenotyping the cytokine-producing dextramer+ and cytokine-producing dextramer− CD4 T
cells corresponding to Th1, Th2 and Th17 subsets of cytokines to determine whether
common cytokine signatures exist in different autoimmune diseases. More recently, we
tested whether dextramers prepared by using naked (fluorochrome-unconjugated) dextran
backbones (kind gift from Immudex) can be used as APCs to stimulate T cells in bioassays.
An amount of 0.07 µg was found sufficient to induce robust proliferative responses in T cell
hybridomas specific to PLP 139–151 and Myhc-α 334–352 (unpublished observations).
These reagents may be useful in studying T cell-specific responses when the contribution of
APCs must be avoided. One such potential application is the evaluation of reactive oxygen
species (ROS) in T cells, whose detection within T cells has been debated, and the argument
made that the T cells derive ROS as a contaminant from APCs.

Can MHC class II dextramers solve all problems with MHC class II
tetramers? If not, what improvements can be made?
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As described above, we have shown the utility of MHC class II dextramers in several
experimental systems, finding the dextramers to be superior to their counterparts in terms of
sensitivity, specificity and applications. If the dextramers can be so much more versatile
than tetramers, a critical question is whether they can be used as reliable reagents to detect
CD4 T cells with varied TCR affinity. Unfortunately, the answer is no. We performed an
experiment to sort the dextramer+ and dextramer− CD4 T cells from PLP 139–151sensitized primary T cell cultures by flow cytometry, expecting that the dextramer− cells
would neither respond to antigen nor bind PLP dextramers upon restimulation. Contrary to
our expectations, however, the dextramer− cells did respond to PLP 139–151 and also
stained with PLP dextramers [15]. We sorted CD4 T cells sensitized with PLP 139–151 that
are negative for PLP 139–151 dextramers, and later stimulated them with PLP 139–151.
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Approximately, 4% of cells from these cultures were found positive for PLP 139–151
dextramers, and expectedly, under similar conditions, the PLP 139–151 tetramer−
counterparts revealed more number of cells (7.2%) to be positive for PLP 139–151
dextramers [15]. These data suggest that a proportion of antigen-responsive T cells, possibly
very low-affinity TCR-bearing cells, may not be detected by dextramers. Thus, the need for
improving the detection sensitivity of dextramers still continues. Reports indicate that preexposure of cells to PKIs enhance the staining intensity of MHC class I tetramers/
dextramers [49, 57]. Mechanistically, PKIs appear to inhibit downregulation of TCRs,
including CD8 co-receptors, leading to their persistence on the surface of T cells [49, 57]. It
is possible that similar strategies may work for MHC class II dextramers, although
participation of CD4 co-receptor is not shown to be critical for binding with MHC class II
tetramers [8, 58].
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In summary, we have analyzed the importance of the utility of MHC class II dextramers,
especially for detecting autoreactive CD4 T cells in relation to tetramers. While tetramers
and other similar reagents (pentamers and protein-A conjugated multimers) are being made
available through several academic (NIH Tetramer Core Facility, Atlanta, GA) and nonacademic sources (Proimmune Inc, Beckman Coulter Inc, and MBL Inc, and TCMetrix Inc),
dextramers are currently available only commercially (Immudex, Denmark). By creating
dextramers for various autoantigens, we showed them to be superior to tetramers with
respect to staining specificity, detection sensitivity, and various applications, but a fraction
of antigen-specific CD4 T cells may still be undetected by dextramers [11–15, 59].
Nonetheless, specifically for ex vivo analysis, the dextramer reagents may offer an
advantage by enumerating the frequencies of antigen-specific T cells directly, thereby
avoiding the need to adopt other laborious procedures like enrichment of tetramer-bound T
cells by magnetic separation [22, 43]. Finally, it should be noted that MHC class II tetramers
are increasingly being used in clinical research in various areas, including, for example,
studies of infectious diseases (Lyme arthritis, pulmonary tuberculosis, cytomegalovirus
infection, and chronic hepatitis), immune-mediated diseases (type I diabetes and multiple
sclerosis), and allergic diseases (atopic dermatitis and rye grass-associated allergy), and for
monitoring T cell responses to vaccines (melanoma, influenza, and anthrax) [9, 17, 21, 47,
60–70]. In all of these evaluations, the frequencies of antigen-specific T cells have been
reported to range from 0.006% to 3.5% in different body fluids, proving that tetramers are
helpful in clinical research. But the real challenge is to be able to reliably detect the T cells
ex vivo in a short period of time without having to stimulate the PBMCs, which is often the
case with the human samples [21, 63]. Such limitations can possibly be overcome with the
availability of MHC class II dextramers, since their detection sensitivity is higher than that
of tetramers [15, 35]. To this end, we are now in the process of creating dextramers for use
in patients with multiple sclerosis. We believe that potential exists for the use of MHC class
II dextramers in both basic and clinical research as the reagents become available.
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Figure 1. Derivation of MHC class II dextramers

To produce soluble MHC class II monomers, two constructs, each representing MHC class
II α and MHC class II β chains, are first created. Generally, we insert the nucleotide
sequence for specific peptides of interest or thrombin-cleavage site-tagged/CLIP into the Nterminal end of the β chain construct. Likewise, Fos-and Jun-sequences are attached to the
C-terminal ends of α and β constructs, respectively, to facilitate stability of α and β chains
during protein expression, whereas the BirA site for biotinylation is introduced in the αconstruct. The constructs are used to express soluble MHC molecules using Baculovirus in
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Sf9 insect cells. After biotinylation, the MHC monomers obtained from the constructs
containing covalently tethered, specific peptide sequences are assembled with dextran
molecules to obtain dextramers directly. In contrast, the biotinylated proteins generated from
the CLIP-tethered constructs are first treated with thrombin to release the CLIP peptide, and
the resulting empty MHC monomers are then used to load peptides of interest exogenously
by peptide-exchange reaction. For dextramerization, the biotinylated MHC monomers
generated from any of the above two approaches are mixed with dextran-SA-fluorochrome
at molar ratios ranging from ~9:1 or 20:1, and the dextramers are then used to stain T cells
to analyze their frequencies by flow cytometry.
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List of MHC class II tetramers and dextramers, and their use for the determination of antigen-specific T cell
responses in mice and humans
MHC class II alleles/epitopes

Application

(a) Tetramers
Mice
IAb

Author Manuscript

IRBP271–290 and IRBP771–790

Thymic selection of T cells [71]

LCMV GP66–77, GP126–140, GP6–20 and CLIP

Detection of LCMV-specific T cells in infected
mice [72]

MOG 35–55, MOG38–49 and hCLIP103–117

Detection of MOG-specific T cells in EAE mice
[40, 73]

OVA323–339, CLIP and LCMV GP61

Detection of OVA-specific T cells in immunized
mice[74]

FliC427–441, 2W1S, OVA323–339

Determination of the frequencies of antigenspecific T cells in naïve repertoires [43]

HY

Detection of antigen-specific T cells in naïve and
immunized mice [75]

IAd
OVA323–339 and influenza HA126–138

Peptide/MHC display and antigen-specificity
studies [8, 76, 77]

IAg7
p8G p6-α62, p8G p11-α72, p8E p6-α62,
p8E p11-α72, insulin, CHGA and HEL

Detection of insulin-specific T cells in NOD mice
[78]

GAD524–543, GAD1040–79, GAD1136–17, p206,
p524, GAD206–220 and GAD471–490

Detection of GAD-specific T cells in NOD mice
[22, 47, 79]

IAk

Author Manuscript

Myhc-α334–352 and RNase43–56

Detection of Myhc-α-specific T cells in EAM
mice [31]

IRBP201–216, and EHC44–59

Detection of IRBP, and IRBP- and EHC-crossreactive T cells in EAU mice [36]

IAs
PLP139–151 and TMEV70–86

Detection of PLP-specific T cells in EAE mice
[33]

PLP139–151 and ACA83–95

Detection of PLP- and ACA-cross-reactive T cells
in EAE mice [14]

IEk
MCC88–103

First report to demonstrate that MHC class II
tetramers detect antigen-specific CD4 T cells [78]

U1–70131–150, U1–70131–150, P(140) and
MCC88–103

TCR-signaling studies, and antigen-specific T cell
responses [58, 80, 81]
Humans

Author Manuscript

DP4
MAGE-3

Detection of MAGE-3-specific T cells in
vaccinated patients [70]

DQ2
αI- and αII-peptides of gliadin

Detection of gliadin-specific T cells in patients
with celiac disease [82]
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DR*1101
MAGE-A3191–205, MAGE-A3281–295 and

Epitope-binding studies [83]

MAGE-A3286–300
DR0301
IGRP peptides and Flu MP169–181

Tetramer-guided epitope mapping [84]

DR0401
IGRP peptides and Flu HA306–318

Tetramer-guided epitope mapping [84]

DRB1
Bet v 1141–155, Der p 1 16–30, Der p 1 171–185
and

T cell responses in allergy [85]

Phl p 1 194–208
DRB1*0101

Author Manuscript

HIV Gag p24294–313, Gag p24264–283, TT830–843,
influenza HA307–319 and CMV pp65108–127

Detection of HIV-, tetanus toxoid-, influenza-, or
CMV-specific T cells by magnetic bead
enrichment [86]

HA307–319 and HA306–318

Detection of influenza-specific T cells [87, 88]

Fel d 1

Detection of Fel d 1-specific T cells in atopic
dermatitis patients [64]

DRB1*0401

Author Manuscript

HA306–318 and GAD

Detection of influenza-specific T cells in vaccinerecipients [88]

MOG97–109

Detection of MOG-specific T cells [89]

OspA164–175

Detection of OspA-specific T cells in lyme
arthritis patients [62]

Human CII, HCgp39 and Osp-A

Detection of cartilage antigen-specific T cells in
rheumatoid arthritis patients [90]

HCV 1248, HCV 1579 and HCV 1770

Detection of HCV-specific T cells in viral
hepatitis [21, 63]

MART 151–173

Detection of MART-1-specific T cells in vaccinerecipients [69]

Lol P1

Detection of allergen-specific T cells in allergic
individuals [65]

DRB1*0402
Dsg3

Detection of Dsg3-specific T cells in pemphigus
vulgaris [91]

DRB1*0404
PA112–127

Detection of antigen-specific T cells in recipients
of Anthrax vaccine [67]

HIV Gag p24164–183 and HCV NS31248–1261

Detection of HIV- or HCV-specific T cells by
magnetic bead enrichment [86]

DRB1*1302

Author Manuscript

PA373–393 and PA381–392

Detection of antigen-specific T cells in recipients
of Anthrax vaccine [67]

DR3
MTB 1–13 and CMV pp65510–522

Detection of MTB- and CMV-specific T cells in
patients/vaccine-recipients [92]

DR4
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HA p306–318 and NY-ESO-1 p119–130

Detection of influenza- or NY-ESO-1-specific T
cells by immunoscope [25]

Ag85B and ESAT-6

Detection of MTB-specific T cells in patients with
pulmonary tuberculosis [61]

DR401
GAD65555–567 and HSV-p61

Detection of GAD-specific T cells in type 1
diabetes [47]

DR404
GAD65555–567 and HSV-p61

Detection of GAD-specific T cells in type 1
diabetes [47]

(b) Dextramers
Mice
IAb

Author Manuscript

MOG 35–55

Detection of MOG-specific T cells in EAE mice
[59]

IAk
Myhc-α 334–352 and RNase 43–56

Detection of Myhc-α-specific T cells in EAM
mice and CVB3-infected mice [11, 15]

IAs
PLP139–151 and TMEV70–86

Detection of PLP-specific T cells ex vivo, in vitro
and in situ in EAE mice [12, 13, 15]

PLP139–151 and ACA83–95

Detection of PLP- and ACA-cross-reactive T cells
in ACA infected mice [14]
Humans

HLA-DR1
Influenza A HA307–319 and HIV-1 p24
Gag299–312

Detection of influenza-specific T cells [49]

Author Manuscript

HLA-DP2
Mim2, Mim2 and Be, and PLXNA4 and Be

Detection of Be-specific T cells [93, 94]

*

This list is intended to capture broad applications of tetramer and dextramer reagents in basic and clinical research, and by no means is a
comprehensive list. As such, some reagents may not have been listed, and the authors wish to acknowledge this limitation.

Author Manuscript

IRBP, interphotoreceptor retinoid-binding protein; LCMV, Lymphocytic choriomeningitis virus; GP, glycoprotein; CLIP, Class II-associated
invariant chain peptide; MOG, myelin oligodendrocyte glycoprotein; EAE, experimental autoimmune encephalomyelitis; OVA, ovalbumin; HA,
hemagglutinin; FLiC, flagellar filament structural protein; HY, Y chromosome-encoded transplantation antigens; NOD, non-obese diabetic; GAD,
glutamic acid decarboxylase; CHGA, chromogranin A; HEL, hen egg lysozyme; Myhc-α, cardiac myosin heavy chain-α; RNase, Ribonuclease;
EAM, experimental autoimmune myocarditis; EHC, Ehrlichia canis; EAU, experimental autoimmune uveitis; PLP, myelin proteolipid protein;
TMEV, Theiler’s murine encephalomyelitis virus; ACA, Acanthamoeba castellanii; MCC, moth cytochrome C; MAGE, melanoma-associated
antigen; IRGP, islet-specific glucose-6-phosphatase catalytic subunit-related protein; MP, Matrix protein; Bet v 1, Betula verrucosa; Der p 1,
Dermatophagoides pteronyssinus; Phl p 1, pollen allergen; HIV, Human immunodeficiency virus; Gag, group-specific antigen; TT, Tetanus toxoid;
CMV, Cytomegalovirus; OspA, Borrelia burgdorferi outer surface protein-A; CII, type 2 collagen; HCV, Hepatitis C virus; MART, from MelanAe/melanoma antigen recognized by T cells; Lol P1, rye grass allergen; HCgp, Human cartilage glycoprotein; Dsg3, desmoglein3; PA, protective
antigen of Bacillus anthracis; NS, nonstructural protein; MTB, Mycobacterium tuberculosis; NY-ESO-1, New York esophageal squamous cell
carcinoma; Ag85B, Antigen 85; ESAT-6, Early Secretory Antigenic Target; CVB3, coxsackie virus B3; Mim2, mimotope-2; Be, beryllium
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Table 2

Author Manuscript

Advantages of using MHC class II dextramers over tetramers for detecting antigen-specific, autoreactive CD4
T cells.
Parameters

Tetramers

Dextramers

a. Generation of reagents
    • Creation of MHC constructs,
      expression of
      soluble MHC monomers and
      biotinylation

Steps are similar for both the reagents

    • Multimerization

Require
fluorophore/streptavidinconjugated molecules

Require
fluorophore/streptavidinconjugated dextran molecules

    • Number of MHC monomers per
      reaction

12.6 × 10−12 moles

2.78 × 10−12 moles

    • Specificity

Yes

Yes, but enhanced

    • Sensitivity

Low

High

    • Duration

Variable (usually 2 to 3
hours in our hands)

Relatively short (0.5 to 2 hours)

    • Detection of T cells ex vivo

May or may not work

Reliable and consistent

    • Detection of T cells activated in
      vitro

Useful

Useful

    • Detection of T cells in situ

May work

Reliable and consistent

    • Cytokine-phenotyping by flow
      cytometry

Yes

Yes, but with enhanced sensitivity

    • Bioassay

Yes

Yes

b. Staining characteristics based on flow cytometry

Author Manuscript

c. Applications

Author Manuscript
Author Manuscript
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